BioVie Inc. Announces Proposed Public Offering

Core Viewpoint - BioVie Inc. is initiating a public offering of its common stock and/or pre-funded warrants, along with accompanying common stock purchase warrants, to raise capital for working and corporate purposes [1][2]. Group 1: Offering Details - The offering will be conducted by ThinkEquity as the sole placement agent and is subject to market conditions, with no assurance on the completion or terms of the offering [2]. - The securities will be offered under a shelf registration statement on Form S-3, which was filed with the SEC and declared effective in August 2023 [3]. Group 2: Company Overview - BioVie Inc. is a clinical-stage company focused on developing innovative drug therapies for advanced liver disease and neurological disorders [5]. - The company's drug candidate NE3107 targets neuroinflammation and insulin resistance, which are associated with Alzheimer's and Parkinson's diseases, showing promising results in clinical trials [5]. - BioVie’s orphan drug candidate BIV201 is under evaluation for treating ascites due to chronic liver cirrhosis and has received FDA Fast Track status [5].